<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=188846"><dc:title>Neurotoxicity of synthetic cannabinoid receptor agonist cumyl-PINACA</dc:title><dc:creator>Jurič,	Damijana Mojca	(Avtor)
	</dc:creator><dc:creator>Bulc Rozman,	Klara	(Avtor)
	</dc:creator><dc:creator>Lipnik Štangelj,	Metoda	(Avtor)
	</dc:creator><dc:creator>Šuput,	Dušan	(Avtor)
	</dc:creator><dc:creator>Brvar,	Miran	(Avtor)
	</dc:creator><dc:subject>synthetic cannabinoid receptor agonists (SCRAs)</dc:subject><dc:subject>cumyl-PINACA (SGT-24)</dc:subject><dc:subject>neurons</dc:subject><dc:subject>astrocytes</dc:subject><dc:subject>neurotoxicity</dc:subject><dc:subject>receptors</dc:subject><dc:description>Background/Objectives: Synthetic cannabinoid receptor agonists (SCRAs) are associated with severe neurotoxicity, but the cellular mechanisms underlying their effects remain poorly defined. We investigated the effects of Cumyl-PINACA (SGT-24), a carboxamide-type SCRA derived from cumylamine, on rat cortical neurons and astrocytes. 
Methods: Primary rat cortical neurons and astrocytes were exposed to 1–10,000 nM SGT-24. Metabolic activity, mitochondrial function, morphology, and cell death were evaluated. Selective antagonists of cannabinoid receptor type 1 (CB1), G protein-coupled receptor 55 (GPR55), peroxisome proliferator-activated receptor gamma (PPARγ), and transient receptor potential cation channel subfamily V member 1 (TRPV1) were used to probe the involvement of these receptor pathways. 
Results: SGT-24 decreased metabolic activity in both cell types in a concentration- and time-dependent manner, with greater potency in neurons (IC50 = 13.2 nM) than in astrocytes (IC50 = 39.8 nM). After 24 h, maximal effects were observed at 100 nM in neurons and 500 nM in astrocytes, reducing metabolic activity by 45.2% and 36.2%, respectively. At these concentrations, mitochondrial membrane potential decreased to 57.6% and 54.1% of control, while cellular ATP levels fell to 51.6% and 52.5%, respectively. Neurons predominantly exhibited early apoptosis (21.9% of cells vs. 3.1% in controls), whereas astrocytes showed mainly 7-aminoactinomycin D (7-AAD)-positive cell death (19.3% vs. 8.2% in controls). Pharmacological inhibition of CB1, TRPV1, and PPARγ attenuated SGT-24-induced metabolic impairment, mitochondrial dysfunction, and apoptosis in neurons, whereas inhibition of CB1 and PPARγ reduced astrocytic toxicity. 
Conclusions: SGT-24 exerts potent, cell-type-dependent neuroglial toxicity associated with mitochondrial dysfunction and distinct cell death patterns, suggesting the involvement of cannabinoid receptor-dependent and non-cannabinoid signalling mechanisms. The nanomolar potency of SGT-24 underscores the toxicological risk posed by high-potency SCRAs.</dc:description><dc:date>2026</dc:date><dc:date>2026-09-29 11:24:03</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>188846</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
